<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metreleptin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metreleptin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metreleptin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="95497" href="/d/html/95497.html" rel="external">see "Metreleptin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="109724" href="/d/html/109724.html" rel="external">see "Metreleptin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F24147898"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Antibody formation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with metreleptin. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of endogenous leptin action and/or loss of metreleptin efficacy. Severe infection and/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of metreleptin efficacy during treatment. Contact Amryt Pharmaceuticals DAC at 1-866-216-1526 for neutralizing antibody testing of clinical samples.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lymphomas:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin. Carefully consider the benefits and risks of treatment with metreleptin in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">REMS program:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because of these risks associated with the development of anti-metreleptin antibodies that neutralize endogenous leptin and/or metreleptin and the risk for lymphoma, metreleptin is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Myalept REMS Program.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24673744"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Myalept</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F23884138"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Leptin Analog</li></ul></div>
<div class="block doa drugH1Div" id="F24151653"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3535dda-ef14-4cf9-ad93-081f3b26a293">Lipodystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lipodystrophy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Baseline weight ≤40 kg: <b>SUBQ: </b>Initial: 0.06 mg/kg once daily; adjust dose by 0.02 mg/kg daily based on response and tolerability (maximum: 0.13 mg/kg once daily).</p>
<p style="text-indent:-2em;margin-left:4em;">Baseline weight &gt;40 kg: <b>SUBQ: </b>Initial: 2.5 mg (males) or 5 mg (females) once daily; adjust dose by 1.25 to 2.5 mg daily based on response and tolerability (maximum: 10 mg once daily).</p>
<p style="text-indent:-2em;margin-left:4em;">Discontinuation: If metreleptin is to be discontinued in a patient who also has risk factors for pancreatitis (eg, history of pancreatitis, severe hypertriglyceridemia), taper the dose over a 1-week period and monitor triglyceride levels; consider initiating or adjusting the dose of lipid-lowering medications as needed.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990726"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988088"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F24151654"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F24151652"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="109724" href="/d/html/109724.html" rel="external">see "Metreleptin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f3535dda-ef14-4cf9-ad93-081f3b26a293">Lipodystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lipodystrophy:</b> Infants, Children, and Adolescents: The manufacturer’s labeling describes use in infants; however, in trials, the minimal inclusion age was 6 months and the youngest subjects reported in trials and case series were at least 1 year of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25734254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25734254'])">Ref</a></span>). <b>Note:</b> Increase or decrease dose based on clinical response (eg, inadequate metabolic control) or other considerations (eg, tolerability issues, excessive weight loss).</p>
<p style="text-indent:-2em;margin-left:4em;">Baseline weight ≤40 kg, male and female patients: SubQ: Initial: 0.06 mg/kg/dose once daily; adjust dose (increase or decrease) in 0.02 mg/kg increments based on response or adverse effects. Maximum daily dose: 0.13 mg/kg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Baseline weight &gt;40 kg:</p>
<p style="text-indent:-2em;margin-left:6em;">Female patients: SubQ: Initial: 5 mg once daily, adjust dose (increase or decrease) in 1.25 to 2.5 mg increments based on response or adverse effects; maximum daily dose: 10 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">Male patients: SubQ: Initial: 2.5 mg once daily, adjust dose (increase or decrease) in 1.25 to 2.5 mg increments based on response or adverse effects; maximum daily dose: 10 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Discontinuation: When discontinuing therapy in patients with risk factors for pancreatitis (eg, history of pancreatitis, severe hypertriglyceridemia), taper the dose over a 1-week period and monitor triglyceride levels; consider initiating or adjusting the dose of lipid-lowering medications as needed.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130085"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51130086"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F24047748"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (13%; includes adjunctive insulin use), weight loss (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (84%; neutralizing: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria at injection site (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (10%), diarrhea (6%), nausea (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ovarian cyst (8%), proteinuria (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (8%), fatigue (8%), paresthesia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (8%), back pain (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otic infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (progression)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Membranoproliferative glomerulonephritis (progression)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anaplastic large cell lymphoma, T-cell lymphoma</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (including inflammation at injection site and local skin hyperpigmentation)</p></div>
<div class="block coi drugH1Div" id="F23877794"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis, urticaria, generalized rash) to metreleptin or any component of the formulation; general obesity (not associated with congenital leptin deficiency)</p></div>
<div class="block war drugH1Div" id="F24147906"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody development: <b>[US Boxed Warning]: Antimetreleptin antibodies with neutralizing activity have been identified with metreleptin use. Consequences could include inhibition of endogenous leptin action and/or loss of metreleptin efficacy; severe infection and/or worsening of metabolic control have been reported. Test patients who develop severe infections or show signs of loss of metreleptin efficacy for anti-metreleptin antibodies with neutralizing activity. Contact the manufacturer (1-866-216-1526) for neutralizing antibody testing of clinical samples.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Generalized hypersensitivity (eg, urticaria, generalized rash) has been reported; instruct patients to promptly seek medical advice regarding discontinuation of metreleptin if hypersensitivity reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphomas: <b>[US Boxed Warning]: T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy (both treated and not treated with metreleptin). Consider the benefits and risks of metreleptin treatment in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy.</b> A causal relationship has not been established; acquired lipodystrophies are associated with autoimmune disorders, and autoimmune disorders are associated with increased risk of malignancy (including lymphoma).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disorders: Progression of autoimmune hepatitis and membranoproliferative glomerulonephritis associated with massive proteinuria and renal failure have been observed; causal relationship with metreleptin treatment has not been established; acquired lipodystrophies themselves are associated with autoimmune disorders. Consider the benefits/risks of metreleptin treatment in patients with autoimmune disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: In patients with risk factors for pancreatitis (eg, history of pancreatitis, severe hypertriglyceridemia) who require discontinuation of metreleptin, taper the dose over a 1-week period and monitor triglyceride levels; evaluate signs/symptoms of pancreatitis. Consider initiating or adjusting the dose of lipid-lowering medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Injection contains benzyl alcohol when reconstituted with bacteriostatic water for injection (BWFI); large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Safety and effectiveness have not been established for the treatment of partial lipodystrophy or liver disease, including nonalcoholic steatohepatitis. Not indicated for use in patients with HIV-related lipodystrophy or for use in patients with metabolic disease (eg, diabetes mellitus, hypertriglyceridemia) without concurrent evidence of congenital or acquired generalized lipodystrophy.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program: <b>[US Boxed Warning]: Access is restricted through a REMS program.</b> Prescribers and pharmacies must be certified with the program; information is available at www.myaleptrems.com or 1-855-669-2537.</p></div>
<div class="block foc drugH1Div" id="F24673745"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myalept: 11.3 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F24147902"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F24942717"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Myalept Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11.3 mg (per each): $7,393.08</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F23907422"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> Administer SUBQ into the abdomen, thigh, or upper arm once daily at the same time every day; administer any time of day without regard to the timing of meals. Rotate injection sites daily. Doses exceeding 1 mL may be administered as 2 equally divided injections.</p></div>
<div class="block admp drugH1Div" id="F52614559"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SubQ: Using a 1 mL syringe or smaller, withdraw desired dose. Smaller syringes may be appropriate for patients ≤25 kg as small volumes for administration can result in medication errors when measured incorrectly; ensure proper syringe size is selected. Administer subcutaneously into the abdomen, thigh, or upper arm once daily at the same time every day; administer any time of day without regard to the timing of meals. Rotate injection sites daily. Doses exceeding 1 mL may be administered as 2 equally divided injections. Do not mix with insulin. If administered at the same time of day as insulin, the same body area may be used for injection; however, use 2 different injection sites.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> If using an insulin syringe to administer metreleptin, the volume conversion is 100 units/mL (eg, 0.1 mg [0.02 mL] = 2 units).</p></div>
<div class="block meg drugH1Div" id="F24170123"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F125390s024lbl.pdf%23page%3D16&amp;token=pZANBvlXwrNuDhHx2u8la4vUWTkBL0MpqbHTaxk5dnwZ3gdhlC9W1SypfY6LKMQid674gnWtIK%2BMtI2VTcqYo7X%2BC9AkMKc2FMdQsKJBOPed2Zu3xui%2BjJF7IJIlFgwv&amp;TOPIC_ID=93975" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125390s024lbl.pdf#page=16</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F23877793"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lipodystrophy:</b> Replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital or acquired generalized lipodystrophy.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for use in patients with HIV-related lipodystrophy or for use in patients with metabolic disease (eg, diabetes mellitus, hypertriglyceridemia) without concurrent evidence of congenital or acquired generalized lipodystrophy.</p></div>
<div class="block cyt drugH1Div" id="F23906842"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F23906839"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Metreleptin may enhance the hypoglycemic effect of Insulins.  Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs and symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Metreleptin may enhance the hypoglycemic effect of Sulfonylureas.  Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs or symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308222"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Because metreleptin can restore metabolic and endocrine function, normal menses may be restored in women with previous amenorrhea; fertility may be restored and pregnancies may occur (Chou 2011; Chou 2013; Maguire 2012).</p></div>
<div class="block pri drugH1Div" id="F24147904"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Reports of use of metreleptin during pregnancy are limited (Chou 2011; Chou 2013; Maguire 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse pregnancy outcomes are associated with lipodystrophy in pregnant women, including eclampsia, gestational diabetes, intrauterine growth retardation, intrauterine death, macrosomia, and miscarriage. Based on in vitro data, metreleptin may inhibit uterine contractility during labor. If use is needed during pregnancy, reconstitution with a preservative-free diluent is recommended; solutions containing benzyl alcohol should be avoided in pregnant women due to association with gasping syndrome in premature infants.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to metreleptin is ongoing. Pregnant women or their health care provider may enroll by calling 1-855-669-2537.</p></div>
<div class="block brc drugH1Div" id="F23907418"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if metreleptin is present in breast milk; however, endogenous leptin is present.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F24151659"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Test for antimetreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs of loss of efficacy (eg, worsened metabolic control). Closely monitor blood glucose in patients on concomitant insulin or insulin secretagogue (sulfonylurea, meglitinide) therapy. If tapering metreleptin in patients at risk for pancreatitis, monitor triglyceride levels.</p></div>
<div class="block pha drugH1Div" id="F24151642"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Recombinant human leptin analog that binds to and activates the human leptin receptor (ObR) (which belongs to the class I cytokine family of receptors that signals through the JAK/STAT transduction pathway) to treat complications of leptin deficiency associated with generalized lipodystrophy.</p></div>
<div class="block phk drugH1Div" id="F24151644"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 4-5 times plasma volume</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: No apparent systemic metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3.8-4.7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 hours (range: 2-8 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Renal (major route); clearance delayed in the presence of leptin antibodies and may be delayed in renal impairment</p></div>
<div class="block phksp drugH1Div" id="F51159552"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Pharmacokinetics may be altered in subjects with renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58210452"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Myalept</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Myalept</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Myalepta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Myalept</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25367549">
<a name="25367549"></a>Araujo-Vilar D, Sánchez-Iglesias S, Guillín-Amarelle C, et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. <i>Endocrine</i>. 2015;49(1):139-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/25367549/pubmed" id="25367549" target="_blank">25367549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17671040">
<a name="17671040"></a>Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. <i>Pediatrics</i>. 2007;120(2):e291-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/17671040/pubmed" id="17671040" target="_blank">17671040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22068254">
<a name="22068254"></a>Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. <i>Endocr Pract</i>. 2011;17(6):922-932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/22068254/pubmed" id="22068254" target="_blank">22068254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23740412">
<a name="23740412"></a>Chou K, Perry CM. Metreleptin: first global approval. <i>Drugs</i>. 2013;73(9):989-997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/23740412/pubmed" id="23740412" target="_blank">23740412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21464293">
<a name="21464293"></a>Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. <i>Proc Natl Acad Sci U S A</i>. 2011;108(16):6585-6590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/21464293/pubmed" id="21464293" target="_blank">21464293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25734254">
<a name="25734254"></a>Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. <i>J Clin Endocrinol Metab</i>. 2015;100(5):1802-1810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/25734254/pubmed" id="25734254" target="_blank">25734254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15983199">
<a name="15983199"></a>Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. <i>Diabetes</i>. 2005;54(7):1994-2002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/15983199/pubmed" id="15983199" target="_blank">15983199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22270436">
<a name="22270436"></a>Maguire M, Lungu A, Gorden P, Cochran E, Stratton P. Pregnancy in a woman with congenital generalized lipodystrophy: leptin's vital role in reproduction. <i>Obstet Gynecol</i>. 2012;119(2 pt 2):452-455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/22270436/pubmed" id="22270436" target="_blank">22270436</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Myalept (metreleptin) [prescribing information]. Dublin, Ireland: Amryt Pharmaceuticals DAC; September 2020.</div>
</li>
<li>
<div class="reference">
                  Myalept (metreleptin) [prescribing information]. Dublin, Ireland: Amryt Pharmaceuticals DAC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11856796">
<a name="11856796"></a>Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. <i>N Engl J Med</i>. 2002;346(8):570-578.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metreleptin-drug-information/abstract-text/11856796/pubmed" id="11856796" target="_blank">11856796</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 93975 Version 117.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
